Altimmune Initiates Pemvidutide Phase 3 Trial
Altimmune starts Phase 3 trial for Pemvidutide
Story updates
12:15:32 PM UTC
SquawkNews
ALT Altimmune initiates performa phase 3 trial of pemvidutide in patients with mash Altimmune - 52-week data readout from performa phase 3 trial anticipated in 2029
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.